Dr. Jayaratna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 E 98th St
Fl 6
New York, NY 10029Phone+1 212-659-5559Fax+1 212-987-4675
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2014 - 2016
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Urology, 2009 - 2014- University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Surgery, 2008 - 2009
Rutgers New Jersey Medical SchoolClass of 2008
Certifications & Licensure
CA State Medical License 2010 - Present
NY State Medical License 2016 - 2026
TX State Medical License 2015 - 2019- American Board of Urology Urology
Publications & Presentations
PubMed
- Prognostic factors and treatment impact on overall survival in patients with renal neuroendocrine tumour.Olamide O Omidele, Christopher Connors, Nikhil Wainganker, Ketan Badani, John Sfakianos
BJUI Compass. 2024-06-01 - 4 citationsTCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancerSharada Mokkapati, Sima P. Porten, Vikram M. Narayan, Amy Lim, Isuru Jayaratna
Molecular Cancer Research. 2020-06-01 - 9 citationsDevelopment of a model to predict prostate cancer at the apex (PCAP model) in patients undergoing robot-assisted radical prostatectomy.Shivaram Cumarasamy, Alberto Martini, Ugo Falagario, Zeynep Gul, Alp Tuna Beksac
World Journal of Urology. 2020-04-01
Journal Articles
- An Evaluation of Race, Ethnicity, Age, and Sex-Based Representation in Phase I to II Renal Cell Carcinoma Clinical Trials in the United StatesIsuru Jayaratna, John P Sfakianos, Ketan K Badani, Urologic Oncology
Authored Content
- An Evaluation of Race, Ethnicity, Age, and Sex-Based Representation in Phase I to II Renal Cell Carcinoma Clinical Trials in the United StatesJune 2018
Research History
- Urologic Oncology Research FellowGenomic research as part of the MD Anderson Bladder Cancer SPORE. Studied bladder cancer molecular subtypes using in vitro and xenograft in vivo models.2014 - 2015
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
